



OPEN ACCESS

EDITED AND REVIEWED BY
Wei Peng,
Chengdu University of Traditional
Chinese Medicine, China

*CORRESPONDENCE

Qi Wang,
✉ wangqi@gzucm.edu.cn
Jiansong Fang,
✉ fangjs@gzucm.edu.cn
Shuhuan Fang,
✉ fangshuhuan@gzucm.edu.cn

[†]These authors have contributed equally
to this work

RECEIVED 23 August 2023
ACCEPTED 22 September 2023
PUBLISHED 06 October 2023

CITATION

Luo Y, Li D, Liao Y, Cai C, Wu Q, Ke H,
Liu X, Li H, Hong H, Xu Y, Wang Q, Fang J
and Fang S (2023), Corrigendum: Systems
pharmacology approach to investigate
the mechanism of Kai-Xin-San in
Alzheimer's disease.
Front. Pharmacol. 14:1239060.
doi: 10.3389/fphar.2023.1239060

COPYRIGHT

© 2023 Luo, Li, Liao, Cai, Wu, Ke, Liu, Li,
Hong, Xu, Wang, Fang and Fang. This is an
open-access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer's disease

Yunxia Luo^{1,2†}, Dongli Li^{1†}, Yanfang Liao^{1†}, Chuipu Cai¹, Qihui Wu¹,
Hanzhong Ke^{3,4}, Xinning Liu¹, Huilin Li², Honghai Hong⁵,
Yumin Xu⁶, Qi Wang^{1,7*}, Jiansong Fang^{1,7*} and Shuhuan Fang^{1,7*}

¹Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China, ²Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China, ³Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States, ⁴Department of Medicine, Harvard Medical School, Boston, MA, United States, ⁵Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ⁶Department of Encephalopathy First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China, ⁷Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China

KEYWORDS

systems pharmacology, Kai-Xin-San, Alzheimer's disease, cholinergic system, neuroinflammation

A Corrigendum on

Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer's disease


by Luo Y, Li D, Liao Y, Cai C, Wu Q, Ke H, Liu X, Li H, Hong H, Xu Y, Wang Q, Fang J and Fang S (2020). *Front. Pharmacol.* 11:381. doi: 10.3389/fphar.2020.00381

In the published article, there was an error in [Figure 8](#) as published. The Iba1 fluorescence image of the cortex and corresponding merged image in the KXS-L group was mistakenly displayed. The corrected [Figure 8](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**FIGURE 8**

Kai-Xin-San (KXS) attenuates microglia activation in scopolamine (SCOP)-induced mice. Immunofluorescence analysis in the hippocampus (CA1) and cortex. Microglia were stained with anti-Iba-1 (red) and the nuclei were stained with DAPI (blue). Scale bar: 50 μ m. Con, control group; SCOP, scopolamine; KXS-L, low-dose Kai-Xin San (1.4 g/kg); KXS-H, high-dose Kai-Xin San (2.8 g/kg); Don, donepezil.